GlobeNewswire

Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026
30/10/2026
JUPITER, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the [...]
Nathan Fielder Meets Ryan ElHosseiny: The Science Behind “The Strip Club” and “Who’s on First” in You Can See Everything
30/10/2026
MIAMI, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Ryan “Egypt” ElHosseiny, brings over 20 years of laboratory diagnostics experience to Nathan Fielder's You Can See Everything . His new short film, Lab Stripping , reveals the [...]
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/10/2026
VANCOUVER, BC and BOSTON, MA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and [...]
Philips launches HyperVue Integrated System in the U.S., bringing advanced coronary imaging and physiology into the cathlab
30/10/2026
New fixed, single-room configuration is designed to make DeepOCT+NIRS Imaging and X1-FFR physiology readily available for efficient cath lab workflows At TCT 2026, Philips will showcase its broader full picture [...]
SRX Global Provides Update on Balance Sheet and Share Buyback
30/10/2026
NORTH PALM BEACH, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in [...]
Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan
30/10/2026
WOODCLIFF LAKE, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has adopted an amendment (the “ [...]
TME Pharma Publishes Its Semi Annual Results and Half-Year Report
30/10/2026
TME Pharma Publishes Its Semi Annual Results and Half-Year Report Berlin, Germany , October 30, 2026, 18:00 CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotech-company with clinical assets for brain cancer [...]
TME Pharma publie ses résultats semestriels et son rapport semestriel
30/10/2026
TME Pharma publie ses résultats semestriels et son rapport semestriel Berlin, Allemagne, le 30 octobre 2026, 18 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), une société de biotechnologie disposant d' [...]
Alps Group Inc Announces Shareholder Approval for a Share Consolidation, Share Capital Increase, and Adoption of Second Amended and Restated Memorandum and Articles of Association
30/10/2026
KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its shareholders [...]
Atsena Therapeutics Reports New Preclinical Data Demonstrating Robust MYO7A Expression and Favorable Safety for ATSN-301, a Laterally Spreading Dual AAV Vector-based Gene Therapy for Usher Syndrome Type 1B
30/10/2026
Dual vector and AAV.SPR technologies combine to drive supraphysiological levels of full-length MYO7A in non-human primate retina, reaching the macula without foveal detachment Six-month GLP toxicology study establishes [...]
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
30/10/2026
Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML) Fully treated, randomized, double-blind n=90 Part A [...]
CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides
30/10/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 30, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company"), today welcomed a significant development in the U.S. regulatory landscape for [...]
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
30/10/2026
Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes [...]
Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
30/10/2026
WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated [...]
Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting
30/10/2026
PRINCETON, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 Congress of Neurological [...]
Sienna Completes Acquisition in Ottawa
30/10/2026
MARKHAM, Ontario, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (" Sienna " or the " Company ") (TSX: SIA) announced today that it has completed its previously disclosed $170.7 million acquisition of [...]
IRADIMED CORPORATION Reports Third Quarter 2026 Financial Results
30/10/2026
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reports revenue of $24.2 million for the third quarter of 2026, which increased by $3.0 million, or 14% compared to the same period in 2025 and increased by $ [...]
Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
30/10/2026
MELBOURNE, Australia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases [...]
NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes
30/10/2026
New results strengthen the foundation for commercial naïve exosome supply and continued development of ExoPTEN TORONTO and HAIFA, Israel, Oct. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum